Document is current
Any future updates will be listed below
-
Authors
Bentaleb, Cyrine
Hervouet, Kévin
Montpellier, Claire
Camuzet, Charline
Ferrié, Martin
Burlaud-Gaillard, Julien
Bressanelli, Stéphane
Metzger, Karoline
Werkmeister, Elisabeth
Ankavay, Maliki
Janampa, Nancy Leon
Marlet, Julien
Roux, Julien
Deffaud, Clarence
Goffard, Anne
Rouillé, Yves
Dubuisson, Jean
Roingeard, Philippe
Aliouat-Denis, Cécile-Marie
Cocquerel, Laurence https://orcid.org/0000-0002-2136-5178
-
Funding
Funding for this research was provided by:
Inserm Transfert (MAT-PI-17006)
Institut Pasteur de Lille (DiagHepE)
Région Hauts-de-France (DiagHepE)
Agence Nationale de Recherches sur le Sida et les Hépatites Virales
Université de Tours
Institut Pasteur De Lille
- License Information
-
More Information
Article History
Received: 26 August 2022
Revised: 4 November 2022
Accepted: 23 November 2022
First Online: 3 December 2022
Declarations
:
: Claire Montpellier, Jean Dubuisson and Laurence Cocquerel are coinventors of two patent applications on the use of antibodies having specificity for the ORF2i protein for HEV diagnostic purposes. Patents have been filed by Inserm Transfert. Julien Roux and Clarence Deffaud are employees of the BIOTEM company. The authors have no other financial or non-financial interests to disclose.
